Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Receivables Refunds (2020 - 2022)

Nurix Therapeutics (NRIX) has disclosed Receivables Refunds for 3 consecutive years, with $204000.0 as the latest value for Q1 2022.

  • Quarterly Receivables Refunds fell 94.88% to $204000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $204000.0 through Feb 2022, down 94.88% year-over-year, with the annual reading at $204000.0 for FY2021, 94.7% down from the prior year.
  • Receivables Refunds for Q1 2022 was $204000.0 at Nurix Therapeutics, roughly flat from $204000.0 in the prior quarter.
  • The five-year high for Receivables Refunds was $4.0 million in Q1 2021, with the low at $204000.0 in Q3 2021.
  • Average Receivables Refunds over 3 years is $2.2 million, with a median of $3.1 million recorded in 2021.
  • The sharpest move saw Receivables Refunds crashed 94.7% in 2021, then crashed 94.88% in 2022.
  • Over 3 years, Receivables Refunds stood at $3.8 million in 2020, then plummeted by 94.7% to $204000.0 in 2021, then changed by 0.0% to $204000.0 in 2022.
  • According to Business Quant data, Receivables Refunds over the past three periods came in at $204000.0, $204000.0, and $204000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.